Pancreatic cancer is a relatively rare cancer with a global age-standardized incidence rate of 4.9. It is the 12 th highest in global incidence with a 5-year prevalence of about 380,000 (WHO, Globocan 2020 ). The low incidence of the cancer may have led to relatively little effort in resolving outstanding medical needs for the indication. However, there has been a steady increase in the incidence of pancreatic cancer globally, primarily observed in developed nations like North America and among younger individuals. It is estimated that by 2040, the number of new incidences would have increased by 70%. Several aspects are thought to contribute to this increase, including lifestyle factors like smoking, alcohol, obesity, and poor diet habits. Along with the consistent increase in incidence, pancreatic cancer also suffers from a very high mortality rate (Figure ). At 4.7 it has the 9th highest global mortality rate and with a mortality rate of 7.6 accounts for the 3rd highest deaths due to cancers in North America, after lung and colorectal cancer (WHO, Globocan 2020, ) 159 A similar situation exists in Europe with a mortality rate of 6.8. Pancreatic cancer has an extremely low survival rate estimated at 2-9% (5 Year), associating it with a poor prognostic readout for patients. Compared to other gastrointestinal cancers, pancreatic and liver cancers are associated with some of the poorest survival prognosis.